在DREAMM-7和DREAMM-8试验中调整贝兰他单抗莫福汀给药方案以平衡疗效与耐受性
在复发/难治性多发性骨髓瘤的DREAMM-7和DREAMM-8试验中,贝兰他单抗莫福汀联合标准治疗显示显著的无进展生存(PFS)获益,DREAMM-7还显示总生存获益。通过描述性分析评估按方案调整剂量对眼部事件管理和疗效的影响,结果显示剂量调整可有效管理眼部事件并允许患者继续治疗获得稳健疗效。
要点
- 剂量调整将贝兰他单抗莫福汀给药间隔中位数延长至8至12周,眼部事件在最初3个月发生率最高后维持低位。
- 几乎全部缓解者(部分缓解或更好)需要剂量调整,多数患者在延长给药延迟(>2周期)前已获得缓解。
- DREAMM-7和DREAMM-8中至少有1次≥12周给药延迟的患者中位PFS分别为36.6个月和未达到。
核心结论
- 眼部事件常见但可通过剂量调整有效管理,使患者得以继续治疗并获得稳健的疗效获益。
研究设计与样本
- 基于DREAMM-7(NCT04246047)和DREAMM-8(NCT04484623)试验的描述性分析,评估剂量调整对眼部事件管理和疗效的影响。
主要发现
- 在基线视力正常且正在接受治疗的患者中,剂量调整将贝兰他单抗莫福汀给药间隔延长至9个月时中位8至12周。
- 双眼视力下降至20/50或更差以及眼部不良反应的患病率在最初3个月最高,后续时间点维持低位。
- ≥2级眼科检查结果后中位缓解时间为12周,因眼部事件导致贝兰他单抗莫福汀停药率低。
- 几乎全部缓解者(部分缓解或更好)需要剂量调整;多数患者在延长(>2周期)给药延迟前已获得缓解,未获得者在后续获得或加深缓解。
- DREAMM-7和DREAMM-8中至少有1次≥12周给药延迟的患者中位PFS分别为36.6个月和未达到。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Belantamab mafodotin (belamaf) combined with standard therapies demonstrated significant progression-free survival (PFS) and overall survival benefits in DREAMM-7 and PFS benefit in DREAMM-8 in relapsed/refractory multiple myeloma. Belamaf dose modifications managed adverse events, including belamaf-related ocular events. Ocular events included ocular adverse reactions (eg, dry eyes, photophobia, eye irritation) and protocol-mandated ophthalmic examination findings. Protocol-recommended dose modifications for ocular events were driven by ophthalmic examination findings and included belamaf dose delays until resolution and reductions. We used descriptive analyses to evaluate the impact of dose modifications on managing ocular events and treatment efficacy. In patients with normal baseline vision who were receiving treatment, dose modifications extended belamaf dosing intervals to a median of 8 to 12 weeks by 9 months; the prevalences of reduced vision to bilateral 20/50 or worse and ocular adverse reactions were highest in the first 3 months and remained low at later time points. The median time to resolution after grade ≥2 ophthalmic examination findings was 12 weeks. Rates of belamaf discontinuations due to ocular events were low. Almost all responders (partial response or better) required dose modifications. Most patients achieved a response before an extended (>2 cycles) dose delay; most who had not, subsequently achieved or deepened their response. In DREAMM-7 and DREAMM-8, the median PFS in patients with ≥1 dose delay of ≥12 weeks was 36.6 months and not reached, respectively. Ocular events were common but effectively managed with dose modifications, allowing for patients to remain on treatment and derive robust efficacy benefit. The trials were registered at www.clinicaltrials.gov as #NCT04246047 (DREAMM-7) and #NCT04484623 (DREAMM-8).
引用
- Mateos MV, Trudel S, Quach H, et al. Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials. Blood Adv. 2025. PMID: 40763276. doi:10.1182/bloodadvances.2025016949
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。